Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Breast Cancer|Metastatic Breast Cancer|HR-Positive Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Sacituzumab Govitecan
Sponsor: Ana C Garrido-Castro, MD
Collaborators: Merck Sharp & Dohme LLC|Gilead Sciences